Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Targets for Drug Action: Overview01:26

Targets for Drug Action: Overview

Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

An integrated phenotypic and molecular approach to identify salinity-tolerant lentil (<i>Lens culinaris</i> Medik) genotypes.

Frontiers in genetics·2026
Same author

Cross-scale bioanalytical integration for decoding tumour regulatory plasticity in oncology.

Critical reviews in oncology/hematology·2026
Same author

Bis(pyridino-<i>o</i>-carboranyl)phosphenium Cation: A Platform for Dual-Site Reactivity.

Inorganic chemistry·2026
Same author

Negative cooperativity drives activity of capsid-directed antivirals against hepatitis B virus.

Science advances·2026
Same author

Analytical quality by design (AQbD)-based RP-HPLC method development and validation for concurrent determination of meloxicam and chlorhexidine in a novel dental <i>in-situ</i> gel for odontalgia.

Drug development and industrial pharmacy·2026
Same author

RNA with Azvudine Incorporated One Nucleotide Upstream of 3'-End Resists Cleavage by SARS-CoV-2 Proofreading Exonuclease.

Research square·2026

Related Experiment Videos

Structure-Based Design of UVRAG-BAX Binding Interface-Targeting Compound Induces Apoptosis and ROS in Breast Cancer

Shiv Kumar1, Raj Bahadur Singh1, Vikash Kumar Dubey1

  • 1School of Biochemical Engineering, Indian Institute of Technology (BHU), Varanasi 221005 Uttar Pradesh, India.

Biochemistry
|May 12, 2026
PubMed
Summary

Researchers identified a novel small molecule targeting the UVRAG-BAX protein interaction. This compound shows potent anticancer activity by inducing apoptosis and cell cycle arrest in breast cancer cells.

Related Experiment Videos

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Pharmacology

Background:

  • Protein-protein interactions are crucial in cancer signaling pathways.
  • Targeting these interactions is a key strategy in anticancer drug discovery.
  • The UVRAG-BAX protein complex is implicated in tumor progression.

Purpose of the Study:

  • To identify small-molecule inhibitors of the UVRAG-BAX protein complex.
  • To evaluate the anticancer potential of identified inhibitors.
  • To elucidate the mechanism of action of lead compounds.

Main Methods:

  • Structure-based drug design including protein-protein docking and virtual screening.
  • Molecular docking to identify potential inhibitors from the ZINC database.
  • MTT assay for cytotoxicity, cell cycle analysis, and confocal microscopy for apoptosis detection.

Main Results:

  • A novel compound, ZINC000002107582, was identified as a potent inhibitor of the UVRAG-BAX interaction.
  • The compound exhibited significant cytotoxicity against MCF-7 breast cancer cells with an IC50 of 5 ± 0.283 μM.
  • Mechanistic studies revealed induction of reactive oxygen species, S-phase cell cycle arrest, and apoptosis.

Conclusions:

  • The identified compound is a promising lead for developing novel anticancer therapeutics targeting the UVRAG-BAX interface.
  • The compound effectively induces cancer cell death through apoptosis and cell cycle disruption.
  • This study highlights the potential of targeting protein-protein interactions for breast cancer treatment.